Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its recent issue, Rebirthel is introduced. In the article, TCR-iPS cell method and DP method which are our patented technologies are discussed properly. Moreover, it mentions about the development of highly universal cells on which Kawamoto Laboratory is conducting the research with the grant support from Japan Agency for Medical Research and Development (AMED). This article is only available to members and only in Japanese. If you have a membership, please visit the site and have a look on the article.
NEWS 2021.3.4 The article introducing Rebirthel was published in the web magazine “Nikkei Biotechnology & Business”